Eupraxia Pharmaceuticals (EPRX) Change in Accured Expenses (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Change in Accured Expenses data on file, last reported at $1.5 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 272.13% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $4.8 million, a 379.24% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, up 430.22% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $1.5 million, down from $1.8 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for EPRX reached as high as $5541.6 billion in Q2 2025 and fell as low as -$5541.6 billion in Q3 2025.
• Historically, Change in Accured Expenses has averaged $289472.8 across 4 years, with a median of $646066.0 in 2023.
• On a YoY basis, Change in Accured Expenses climbed as much as 159055802.69% in 2024 and fell as far as 807847903.51% in 2024.
• Year by year, Change in Accured Expenses stood at $646066.0 in 2023, then surged by 34.79% to $870816.0 in 2024, then surged by 102.43% to $1.8 million in 2025, then declined by 12.67% to $1.5 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $1.5 million in Q1 2026, $1.8 million in Q4 2025, and -$5541.6 billion in Q3 2025.